CL2017002256A1 - Análogos de amilina - Google Patents

Análogos de amilina

Info

Publication number
CL2017002256A1
CL2017002256A1 CL2017002256A CL2017002256A CL2017002256A1 CL 2017002256 A1 CL2017002256 A1 CL 2017002256A1 CL 2017002256 A CL2017002256 A CL 2017002256A CL 2017002256 A CL2017002256 A CL 2017002256A CL 2017002256 A1 CL2017002256 A1 CL 2017002256A1
Authority
CL
Chile
Prior art keywords
amylin analogues
analogs
diabetes
disorders
prevention
Prior art date
Application number
CL2017002256A
Other languages
English (en)
Inventor
Rasmus Just
Dieter Wolfgang Hamprecht
Oliver Demmer
Lise Giehm
Jesper Sloth VILLADSEN
Jolanta Skarbaliene
Maria Alexandrovna Deryabina
Jesper Mosolff Mathiesen
Kofoed Munchhenrik
Original Assignee
Boehringer Ingelheim Int
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002256(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Zealand Pharma As filed Critical Boehringer Ingelheim Int
Publication of CL2017002256A1 publication Critical patent/CL2017002256A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La preserite invención se refiere a análogos de amilina y a su uso en el tratamiento o prevención de varias enfermedades, afecciones o trastornos, incluyendo obesidad, consumo excesivo de alimentos y enfermedades metabólicas asociadas tales como diabetes. Los análogos tienen una buena estabilidad fisica y quimica, buena solubilidad y una larga duración de acción, y son adecuados para su uso en forma de una formulación líquida.</p>
CL2017002256A 2015-03-18 2017-09-06 Análogos de amilina CL2017002256A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15159737 2015-03-18

Publications (1)

Publication Number Publication Date
CL2017002256A1 true CL2017002256A1 (es) 2018-04-02

Family

ID=52779493

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002256A CL2017002256A1 (es) 2015-03-18 2017-09-06 Análogos de amilina

Country Status (19)

Country Link
US (2) US10766939B2 (es)
EP (1) EP3271381B1 (es)
JP (1) JP6769984B2 (es)
KR (1) KR20170126504A (es)
CN (1) CN107567459B (es)
AR (1) AR103954A1 (es)
AU (1) AU2016232218B2 (es)
BR (1) BR112017019378A2 (es)
CA (1) CA2979950A1 (es)
CL (1) CL2017002256A1 (es)
CO (1) CO2017008870A2 (es)
EA (1) EA035791B1 (es)
IL (1) IL253924A0 (es)
MX (1) MX2017011182A (es)
PE (1) PE20180497A1 (es)
PH (1) PH12017501674A1 (es)
SG (1) SG11201707286UA (es)
TW (1) TW201706294A (es)
WO (1) WO2016146739A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083164B2 (en) 2016-09-09 2024-09-10 Zealand Pharma A/S Amylin analogues

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
CA3116023A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
WO2021094259A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
KR20230040943A (ko) * 2020-04-20 2023-03-23 아이투오 테라퓨틱스, 인코포레이티드 1형 당뇨병에 대한 우수한 혈당 제어를 제공하기 위한 인간 아밀린 유사체 폴리펩타이드의 용도
AU2021322137A1 (en) 2020-08-07 2023-01-19 Boehringer Ingelheim International Gmbh Soluble NPY2 receptor agonists
CN116322741A (zh) 2020-09-24 2023-06-23 古布拉有限公司 具有改善的胰淀素受体(hAMY3R)效力的hAM15-52类似物
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
CN113893349B (zh) * 2021-12-13 2022-07-22 北京大学第三医院（北京大学第三临床医学院） 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途
WO2023227133A1 (zh) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途
KR20240099373A (ko) * 2022-05-30 2024-06-28 질랜드 파마 에이/에스 아밀린 유사체의 액체 제제
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
CA2100745C (en) 1991-11-19 2007-07-31 Laura S. L. Gaeta Amylin agonist peptides and uses therefor
US6114304A (en) 1993-09-07 2000-09-05 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
PT929567E (pt) 1996-09-09 2005-07-29 Zealand Pharma As Sintese em fase solida de peptidos
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
HUP0200297A3 (en) 1999-03-17 2002-09-30 Novo Nordisk As Method for acylating peptides and the glutaminic acid derivatives as acylating agents
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
EP2422807A3 (en) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
DK2370461T3 (da) 2008-12-15 2013-12-16 Zealand Pharma As Glucagonanaloger
JP5635530B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
ES2550761T3 (es) 2009-11-25 2015-11-12 Novo Nordisk A/S Método para producción de polipéptidos
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
PE20130338A1 (es) 2010-06-24 2013-03-16 Zealand Pharma As Analogos del glucagon
AU2012266269B2 (en) 2011-06-10 2017-04-06 Novo Nordisk A/S Polypeptides
BR112014015681A2 (pt) 2011-12-23 2019-09-24 Boehringer Ingelheim Int análogos de glucagon
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
CN104395338B (zh) * 2012-04-19 2019-05-10 诺和诺德股份有限公司 人胰岛淀粉样多肽类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) * 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
DK3137494T3 (da) 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
ES2887370T3 (es) 2014-09-04 2021-12-22 Novo Nordisk As Nuevo agonista del receptor de amilina y calcitonina
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083164B2 (en) 2016-09-09 2024-09-10 Zealand Pharma A/S Amylin analogues

Also Published As

Publication number Publication date
CA2979950A1 (en) 2016-09-22
MX2017011182A (es) 2018-06-06
PE20180497A1 (es) 2018-03-09
AU2016232218B2 (en) 2020-09-10
EP3271381B1 (en) 2021-09-08
TW201706294A (zh) 2017-02-16
US20160272693A1 (en) 2016-09-22
KR20170126504A (ko) 2017-11-17
JP2018510871A (ja) 2018-04-19
WO2016146739A1 (en) 2016-09-22
JP6769984B2 (ja) 2020-10-14
PH12017501674A1 (en) 2018-03-12
US10766939B2 (en) 2020-09-08
AR103954A1 (es) 2017-06-14
BR112017019378A2 (pt) 2019-02-19
US20210115104A1 (en) 2021-04-22
SG11201707286UA (en) 2017-10-30
EP3271381A1 (en) 2018-01-24
IL253924A0 (en) 2017-10-31
EA035791B1 (ru) 2020-08-11
EA201791617A1 (ru) 2018-02-28
CN107567459B (zh) 2021-09-24
CO2017008870A2 (es) 2017-11-10
AU2016232218A1 (en) 2017-09-21
CN107567459A (zh) 2018-01-09

Similar Documents

Publication Publication Date Title
CL2017002256A1 (es) Análogos de amilina
CO2019002159A2 (es) Análogos de amilina
IL284423B (en) Antisense oligonucleotides for the treatment of Pompe disease
IL264413B (en) Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
EA201590058A1 (ru) Аналоги глюкагона
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
CO2017011483A2 (es) Pajita comestible para consumir bebidas
BR112017007281A2 (pt) composição ativa de amaciante de tecidos
CL2016002337A1 (es) Uso de derivados de trifluoroetilsulfóxido sustituidos con n-arilamidina para combatir parásitos mediante riego, aplicación por goteo, aplicación por inmersión, inyección en el suelo o mediante el tratamiento de semillas
ECSP15009391A (es) siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS
CL2017001773A1 (es) Análogos de calcitonina para tratar enfermedades y trastornos.
AR100832A1 (es) Composición que comprende bromadiolona, cebo rodenticida y proceso para combatir roedores blancos nocivos
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
ZA201707937B (en) Novel spot-on active substance formulation
UY36354A (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
ES1117305Y (es) Despertador para activar la incorporación del usuario.
CL2012003253A1 (es) Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico.
EA201492173A1 (ru) Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе
ITUA20162607A1 (it) Composizione attiva per il trattamento degli olivi
GT201600190A (es) Compuestos químicos
PL407015A1 (pl) Wyrób cukierniczy
CN302470904S (zh) 按摩器(激战少尉)